» Articles » PMID: 23471889

Hepatic Manifestations of Metabolic Syndrome

Overview
Specialty Endocrinology
Date 2013 Mar 9
PMID 23471889
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of metabolic syndrome is growing around the world at an alarming rate. Obesity involves a plethora of molecules that predispose individuals to an inflammatory state and various metabolic complications. Dysregulation of nutrient metabolism is a key step during the progression of chronic liver disease that induces an inflammatory state, cellular damage, and impaired hepatic insulin signaling, which leads to insulin resistance. Insulin resistance arises from multiple defects in the liver, adipose tissues, and muscle signaling, which leads to a failure to suppress hepatic gluconeogenesis and glycogenolysis, thereby enhancing fat accumulation in the hepatocytes via increased lipolysis and increased hepatic synthesis of triglycerides. This metabolic condition also increases the frequency of other comorbidities such as liver and biliary diseases. Nonalcoholic fatty liver disease is the hepatic expression of metabolic syndrome, which comprises a spectrum of clinical and histological events ranging from simple and benign fatty liver to steatohepatitis, which is characterized by the abnormal activation of pathways leading to an aggressive inflammatory condition. This pathological state may progress to more severe damage known as cirrhosis, which endangers the anatomy and function of liver tissue. In addition, a small group of patients with end-stage liver disease may develop hepatocellular carcinoma and finally death. By contrast, cholesterol gallstone disease is a common metabolic disease, and is considered to be the main biliary indicator of metabolic syndrome. This review provides a detailed summary of the hepatic manifestations associated with metabolic syndrome. Copyright © 2013 John Wiley & Sons, Ltd.

Citing Articles

Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review.

Arteaga I, Chacon C, Martinez-Escude A, Rojano I, Diez-Fadrique G, Carmona-Cervello M Diagnostics (Basel). 2025; 15(3).

PMID: 39941229 PMC: 11816681. DOI: 10.3390/diagnostics15030299.


Exploring the Regulatory Effect of LPJZ-658 on Copper Deficiency Combined with Sugar-Induced MASLD in Middle-Aged Mice Based on Multi-Omics Analysis.

Li C, Liu Z, Wei W, Chen C, Zhang L, Wang Y Nutrients. 2024; 16(13).

PMID: 38999758 PMC: 11243161. DOI: 10.3390/nu16132010.


Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.

Nishihara T, Miyoshi T, Nakashima M, Miki T, Toda H, Yoshida M Cardiovasc Diabetol. 2024; 23(1):167.

PMID: 38730426 PMC: 11088086. DOI: 10.1186/s12933-024-02268-1.


Evaluation of the non-alcoholic fatty liver fibrosis score in predicting short-term outcomes and severe coronary artery disease in patients undergoing coronary computed tomography angiography.

Colak E, Acar B, Cakir O, Celikyurt U, Baris O, Torun A Postepy Kardiol Interwencyjnej. 2024; 20(1):45-52.

PMID: 38616939 PMC: 11008510. DOI: 10.5114/aic.2024.136405.


The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population.

Choe E, Kang H Sci Rep. 2024; 14(1):6118.

PMID: 38480828 PMC: 10937929. DOI: 10.1038/s41598-024-56796-7.